Mexico’s competition regulator COFECE has announced the start of a thorough market study, aimed at the generic drug market.
The regulator said it is concerned with finding out why, out of approximately 350 “single source” medicines obtained by the Public Health sector through direct no-contest contracts, up to 63% are not patent-protected. However, despite this lack of protection, no rival makers have appeared to challenge these products’ sole manufacturers or distributors.
“International evidence indicates that, when a patent on an innovative medication run out, the arrival of several ‘generics’ makers is a boon to competition, translating into lower prices and a greater range of options for consumers” said the COFECE.
After conducting their investigation, the agency is expected to make a series of recommendations and proposals aimed at improving free competition in this market, including any necessary sanctions or remedies to correct failings in the market.
Full Content: América Economía
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI